[1] Tong Jing, Li Pengfei,.Meta Analysis of Efficacy and Safety of Huangkui Capsule Combined with ACEI/ ARB Drugs in the Treatment of Chronic Nephritis [J]. Modern Traditional Chinese Medicine, 2020, (05): 29-38. [doi: 10.13424/j.cnki.mtcm.2020.05.008]
Meta Analysis of Efficacy and Safety of Huangkui Capsule Combined with ACEI/ ARB Drugs in the Treatment of Chronic Nephritis
- Article number:
- 1672-0571(2020)05-0029-11
- Keywords:
- Huangkui capsule; Chronic nephritis; ACEI. ; ARB; Meta analysis
- ZTFLH:
- R692.3
- Code:
- A
- Abstract:
- Objective To systematically evaluate the efficacy and safety of Huangkui capsule combined with ACEI/ARB drugs in the treatment of chronic nephritis ( CGN) , providing evidence - based reference for clinical practice. Methods To Search in PubMed, Medline, Cochrane Library, EMBASE, Chinese Biomedical Literature Database, Wanfang Database, CnKI, and Weipu journal database and collect randomized controlled trials ( RCTS) or semi – rcTs ( qRCT) of Huang Kui capsule combined with ACEI/ ARB drugs for CGN. The RevMan 5. 3 statistical software is used for Meta analysis. Results A total of 35 ITEMS of RCT or qRCT and 2505 patients were included. Meta analysis results indicated that the experimental group could reduce the urinary protein quantification ( 24hUTP) of CGN patients for 24h [ OR = 0. 38, 95%CI ( 0. 30, 0. 46) , P < 0. 00001] , serum creatinine ( Scr) [ OR = 14. 58, 95%CI ( 6. 57, 22. 60) , P=0. 001] and urinary nitrogen ( BUN) [ OR = 0. 54, 95%CI ( 0. 28, 0. 79) , P < 0. 0001] compared with the control group, increasing plasma albumin ( ALB) in CGN patients [ OR = 4. 10, 95% CI ( 2. 07, 6. 13) , P < 0. 0001] . The total effective rate of CGN patients was improved [ OR = 4. 61, 95% CI ( 3. 59, 5. 91) , P < 0. 00001] , reducing the incidence of adverse reactions in patients [ OR = 1. 88, 95% CI ( 1. 09, 3. 24) , P = 0. 02] . Conclusion Compared with ACEI/ ARB drugs alone, Huangkui capsule combined with ACEI/ ARB drugs can improve the total effective rate, reducing 24hUTP, Scr and BUN, increasing ALB, and reducing the occurrence of adverse reactions in patients. Subgroup analysis showed that the treatment of CGN in the test group was better than the control group.
References:
[1]俞东容,王永钧.慢性肾炎与肾风[J].中国中西医结合肾病杂志,2010,11(4):355-356.
[2]刘俊,陈香美.蛋白尿加速肾小管损伤的作用机制[J].中华肾病研究电子杂志,2014,3(2):99-103.
[3]韦志军.ACEI在糖尿病肾病中对肾脏的保护作用[J].中外医学研究,2012,10(15):148-150.
[4]陈孜瑾.血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展[J].肾脏病与透析肾移植杂志,2017,26(5):467-470.
[5]孟宪杰,张侃,时洪娟,等.黄葵胶囊治疗糖尿病肾病的研究概况[J].江苏中医药,2017,49(11):81-85.
[6]侯敬涛,汪翩,刘山.黄葵胶囊联合厄贝沙坦治疗慢性肾小球肾炎的临床分析[J].现代诊断与治疗,2015,26(4):803-804.
[7]刘志.黄葵胶囊联合贝那普利治疗慢性肾炎34例疗效观察[J].中医药导报,2010,16(5):57-58.
[8]刘春生.黄葵胶囊与缬沙坦联合治疗慢性肾小球肾炎蛋白尿的疗效观察[J].临床医学研究与实践,2017,2(13):84-85.
[9]卢静.黄葵胶囊联合氯沙坦治疗慢性肾小球肾炎28例疗效观察[J].中国实用医药,2013,8(2):149-150.
[10]吴宝明.慢性肾小球肾炎应用黄葵胶囊治疗与厄贝沙坦治疗的效果研究[J].医药,2016,7(2):187.
[11]吴鹏.黄葵胶囊与缬沙坦联用治疗慢性肾小球肾炎患者的临床疗效评价[J].抗感染药学,2017,14(3):675-676.
[12]周瑞琴,孟国政,孙书敏.缬沙坦联合黄葵胶囊治疗慢性肾炎疗效观察[J].右江医学,2010,38(4):430-431.
[13]唐利群.氯沙坦钾联合黄葵胶囊治疗慢性肾小球肾炎的效果分析[J].中国医学前沿杂志,2016,8(11):64-67.
[14]庄德晶.缬沙坦联合黄葵胶囊治疗慢性肾小球肾炎的临床疗效观察[J].中西医结合心血管病电子杂志,2017,5(22):184.
[15]张建军,袁劲.缬沙坦联合黄葵治疗慢性肾小球肾炎的疗效观察[J].中国生化药物杂志,2014,34(7):141-143.
[16]张瑜琪,冯爱桥.黄葵胶囊联合缬沙坦胶囊治疗慢性肾小球肾炎的疗效观察[J].中国医院用药评价与分析,2016,16(12):1630-1632.
[17]徐文君,吴国伟,郑卫华.黄葵胶囊联合厄贝沙坦治疗慢性肾小球肾炎临床观察[J].浙江中医杂志,2013,48(2):153-154.
[18]朱开颜,毕春艳.黄葵胶囊治疗慢性肾小球肾炎蛋白尿的疗效观察[J].中国实用医药,2010,5(17):122-123.
[19]朱敏,吴庭龙,朱红兵.黄葵胶囊联合氯沙坦降低慢性肾小球肾炎蛋白尿及肾功能保护作用的临床研究[J].实用临床医药杂志,2013,17(23):96-98.
[20]李伟,韩达妮,李娇艳,等.黄葵胶囊联合氯沙坦对慢性肾炎湿热证患者CRP及TNF-α的影响[J].中国中西医结合肾病杂志,2013,14(10):907-908.
[21]李胜.黄葵胶囊联合美卡素治疗慢性肾小球肾炎蛋白尿的临床观察[J].内蒙古中医药,2017(18):12-13.
[22]李鹏飞,黄成,李丽阳,等.黄葵胶囊联合缬沙坦治疗慢性肾小球肾炎的疗效观察[J].中国伤残医学,2016,24(7):100-101.
[23]潘淑杰,国春玲,杨庆春,等.替米沙坦联合黄葵胶囊在慢性肾小球肾炎患者中的应用及对白细胞介素-6和肿瘤坏死因子-α的影响研究[J].重庆医学,2017,46(A02):31-32.
[24]潘菊香,任云诚,蒲冠军,等.黄葵胶囊联合氯沙坦钾治疗慢性肾炎蛋白尿的临床研究[J].实用临床医药杂志,2014,18(11):122-124.
[25]王光辉.坎地沙坦联合黄葵胶囊治疗慢性肾炎蛋白尿的临床疗效观察[J].现代诊断与治疗,2014,25(22):5126-5127.
[26]王琦,陈富华,王筱霞.缬沙坦联合黄葵胶囊治疗慢性肾小球肾炎的疗效评价[J].三峡大学学报,2017,(s1):69-70.
[27]白芝蕙.黄葵胶囊联合替米沙坦片治疗慢性肾小球肾炎的效果研究[J].当代医药论丛,2017,15(18):19-20.
[28]虞旭光,李丹,唐补生,等.黄葵胶囊联合洛汀新治疗慢性肾炎的疗效观察[J].临床医学,2005,25(7):17-18.
[29]邢丽,赵石磊,王德润,等.黄葵胶囊联合氯沙坦对慢性肾炎患者小管功能保护作用的临床观察[J].中国中西医结合肾病杂志,2011,12(1):72-73.
[30]郑海瑞,王素平.厄贝沙坦联合黄葵胶囊治疗慢性肾炎尿蛋白疗效观察[J].疾病监测与控制,2016,10(10):846-847.
[31]金碧辉,杨立宏.厄贝沙坦联合黄葵胶囊治疗慢性肾小球肾炎的效果观察[J].中国当代医药,2017,24(30):89-91.
[32]陈剑钢,李红,行延霞,等.黄葵胶囊治疗慢性肾小球肾炎蛋白尿的疗效观察[J].山西医药杂志,2016,45(23):2785.
[33]陈勇,欧玉玲.黄葵胶囊联合ACEI降低慢性肾小球肾炎蛋白尿的临床研究[J].中外医学研究,2014,12(19):30-32.
[34]陈文君,周雪娟.厄贝沙坦联合黄葵胶囊治疗慢性肾小球肾炎的疗效观察[J].临床合理用药杂志,2016,9(28):63-64.
[35]陈晚先,万秋华,伍军,等.黄葵胶囊联合替米沙坦治疗慢性肾小球肾炎的临床疗效观察[J].中华临床医师杂志,2016,10(7):195.
[36]雷红英.黄葵胶囊治疗慢性肾小球肾炎蛋白尿的疗效观察[J].河北医科大学学报,2013,34(1):60-61.
[37]霍贝尔,王洪奇.黄葵胶囊治疗慢性肾小球肾炎蛋白尿患者的疗效[J].医疗装备,2017,30(17):121-122.
[38]韩彦萍.黄葵胶囊联合贝那普利治疗慢性肾炎34例疗效观察[J].内蒙古中医药,2014,33(14):21-22.
[39]高利丽.黄葵胶囊联合厄贝沙坦治疗慢性肾小球肾炎的临床观察[J].中国中西医结合肾病杂志,2012,13(3):236-237.
[40]黄朝莉,徐秀蓉,宁成.黄葵胶囊联合厄贝沙坦治疗慢性肾炎蛋白尿患者的疗效观察[J].中国医药指南,2011,9(34):14-16.
[41]高燕.慢性肾小球肾炎的临床诊治[J].中外健康文摘,2010,7(5):236-237.
[42]谢华.补肾健脾活血祛湿方治疗慢性肾炎80例临床观察[J].中国中医药科技,2012,19(6):548.
[43]黎晶晶,徐柏颐.黄蜀葵花黄酮类化合物的化学成分及药理作用研究进展[J].安徽农业科学,2017,45(7):120-124
[44] Zhang L, Li P, Xing C Y, et al. Efficacy and Safety of Abelmoschus manihot for Primary Glomerular Disease: A Prospective, Multicenter Randomized Controlled Clinical Trial[ J] . Am J Kidney Dis, 2014, 64( 1) :57 -65.
[45] Liu Z, Liu S J, Zhou L, et al. Effects of HuangKui capsules on glibenclamide pharmacokinetics in rats[ J] . JEthnopharmacology, 2012, 139( 1) :1 -5.
[46] Zhi M M, Shan M S, Yi G W et al. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/ Akt pathways, compared to α - lipoic acid[ J] . J Ethnopharmacology, 2015, 173:256 -265.
[47] Wei W , Wei H , Wen B H , et al. Inhibition of Akt/ mTOR/ p70S6K Signaling Activity With Huangkui Capsule Alleviates the Early Glomerular Pathological Changes in Diabetic Nephropathy[ J] . Front Pharmacol, 2018, 9: 1 -17.
[48] Zhao Q , Wan Y , Sun W , et al. Effects of huangkui capsule on renal inflammatory injury by intervening p38MAPK signaling pathway in rats with adriamycin - induced nephropathy[ J] . China J. Chin. Mater. Med, 2012, 37( 19) :2926 -2934.
[49] Tu Y , Sun W , Wan Y G , et al. Huangkui capsule, an extract from Abelmoschus manihot ( L. ) medic, ameliorates adriamycin - induced renal inflammation and glomerular injury via inhibiting p38MAPK signaling pathway activity in rats [ J] . J Ethnopharmacology, 2013, 147( 2) :311 -320.
[50] Cai H D , Su S L , Qian D W , et al. Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids[ J] . J Ethnopharmacology, 2017, 206( 12) :152 -159
Memo
基金项目:西安医学院第一附属医院科研项目(XYFY2015-04) 通讯作者:李鹏飞,中级药师?E-mail:475118038@qq.com